Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenue
253
254
259
250
184
125
Revenue Growth (YoY)
-2%
-2%
4%
36%
47%
25%
Cost of Revenue
182
185
181
161
117
84
Gross Profit
70
69
78
89
66
41
Selling, General & Admin
52
56
52
52
39
23
Research & Development
4
5
6
3
2
1
Operating Expenses
55
59
56
52
40
23
Other Non Operating Income (Expenses)
--
--
--
--
--
--
Pretax Income
7
2
14
36
25
19
Income Tax Expense
3
2
3
10
6
2
Net Income
3
0
10
25
18
17
Net Income Growth
-50%
-100%
-60%
39%
6%
-6%
Shares Outstanding (Diluted)
2,027.83
2,031.41
2,069.71
2,084.43
2,115.68
2,078.53
Shares Change (YoY)
0%
-2%
-1%
-1%
2%
12%
EPS (Diluted)
0
0
0
0.01
0
0
EPS Growth
-37%
-92%
-57.99%
43%
5%
-16%
Free Cash Flow
41
14
11
14
-6
16
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
27.66%
27.16%
30.11%
35.6%
35.86%
32.8%
Operating Margin
5.92%
3.93%
8.1%
14.39%
13.58%
13.6%
Profit Margin
1.18%
0%
3.86%
10%
9.78%
13.6%
Free Cash Flow Margin
16.2%
5.51%
4.24%
5.6%
-3.26%
12.8%
EBITDA
--
47
56
65
48
29
EBITDA Margin
--
18.5%
21.62%
26%
26.08%
23.2%
D&A For EBITDA
--
37
35
29
23
12
EBIT
15
10
21
36
25
17
EBIT Margin
5.92%
3.93%
8.1%
14.39%
13.58%
13.6%
Effective Tax Rate
42.85%
100%
21.42%
27.77%
24%
10.52%
Follow-Up Questions
What are Frontage Holdings Corp's key financial statements?
What are the key financial ratios for FGHQF?
How is Frontage Holdings Corp's revenue broken down by segment or geography?
Is Frontage Holdings Corp profitable?
Does Frontage Holdings Corp have any liabilities?
How many outstanding shares for Frontage Holdings Corp?
Key Stats
Prev.Close
$0.1498
Open
$0.1498
Day's Range
$0.1498 - $0.1498
52 week range
$0.101 - $0.1498
Volume
130
Avg.Volume
0
EPS (TTM)
0.00
Dividend yield
--
Market Cap
$303.7M
What is FGHQF?
Frontage Holdings Corp. engages in the provision of research and analytical and development services throughout the drug discovery and development process. The company is headquartered in Exton, Pennsylvania and currently employs 1,560 full-time employees. The company went IPO on 2019-05-30. The company provides laboratory and related services to pharmaceutical and agrochemical companies, as well as bioequivalence clinical and chemical services. The firm has two main divisions: Global Laboratory Services and Global Drug Discovery & Development Services. The Global Laboratory Services division offers laboratory testing support for clients involved in drug development. The Global Drug Discovery & Development Services division includes Drug Development Unit, the Drug Discovery Unit, and the Pharmaceutical Product Development Unit. Its Global Laboratory Services encompass regulated and non-regulated bioanalysis (both small and large molecules), biomarkers, genomics, manufacturing and controls analytical testing, and central laboratory services. The Drug Development Unit includes drug metabolism and pharmacokinetics, Safety and Toxicology. The firm's segments include North America and Europe and PRC.